Intravenous Oxytocin for Post Operative Pain After Minimally Invasive Hysterectomy
Status:
Not yet recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
This double-blinded, placebo-control trial clinical trial aims to investigate the effect of
IV oxytocin infusion on peri-operative opioid consumption following a minimally invasive
hysterectomy under general anesthesia.
patients population will be women who have been scheduled for an elective, minimally invasive
hysterectomy at Beth Israel Deaconness Medical Center.
We hypothesize that, compared to a placebo, exposure to intravenous (IV) oxytocin will reduce
the amount of opioid consumption for women after a minimally invasive hysterectomy procedure.